Unraveling the Risks: Epidemiology of Complicated Pneumococcal Bloodstream Infections

揭示风险:复杂性肺炎球菌血流感染的流行病学

阅读:1

Abstract

Background Invasive pneumococcal infections, such as bacteremia, remain associated with substantial morbidity and mortality, particularly among individuals with underlying health conditions. The primary objective of this study was to evaluate the association between patient comorbidities, particularly chronic cardiac disease, and the development of complicated pneumococcal bacteremia. Secondary objectives included assessing vaccine coverage and clinical outcomes among high-risk patients. Methods We retrospectively reviewed medical records of patients admitted to SSM Health and St. Louis University Hospitals between 2018 and 2024 with confirmed invasive Streptococcus pneumoniae infection. Data collected included demographics, comorbidities, vaccination status, and clinical presentation. Complicated bacteremia was defined as bacteremia with concurrent invasive organ involvement, including endocarditis, septic arthritis/osteomyelitis, or empyema. Multivariable regression analysis was performed, with statistical significance set at P <0.05. Results Among 153 patients, older age, pre-existing heart disease, and congestive heart failure were significantly associated with complicated bacteremia. Common complications included endocarditis, septic emboli, empyema, and pneumonia. Laboratory markers of disease severity included hypoalbuminemia and leukocytosis. More than half of the patients with complicated bacteremia required intensive care unit admission. Vaccination rates were low among patients who developed complicated bacteremia. Conclusions Older age and pre-existing cardiac disease were key predictors of complicated pneumococcal bacteremia. Despite advances in vaccination and antimicrobial therapy, invasive pneumococcal disease continues to cause significant morbidity and mortality. Understanding the epidemiology and risk factors associated with complicated pneumococcal infections is critical for improving prevention, guiding early recognition, and optimizing patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。